A-Alpha Bio

A-Alpha Bio, founded in 2017, has developed a proprietary, integrated platform combining high-throughput experimental biology (AlphaSeq) with machine learning (AlphaBind) to decode and engineer protein-protein interactions. The company has measured over a billion interactions to date, creating a unique data asset to fuel predictive models for therapeutic design. Operating primarily as a platform and services partner, A-Alpha Bio enables partners to discover rare antibodies, identify degradable neo-substrates for targeted protein degradation, and optimize protein interfaces, thereby de-risking and accelerating early-stage drug discovery.

Integrated platform combining AlphaSeq (high-throughput synthetic biology for quantitative measurement of millions of protein-protein interactions via yeast surface display and DNA barcoding) and AlphaBind (machine learning models trained on the interaction database to predict binding affinity from sequence and design optimized proteins).

A-Alpha Bio competes with other AI-driven drug discovery companies (e.g., Recursion, Exscientia, Absci), traditional biologics discovery CROs, and internal R&D efforts at large biopharma. Its primary differentiation is the closed-loop generation of its own massive, quantitative experimental dataset, which is unique in scale and quality compared to competitors who often rely on heterogeneous public or legacy data.